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Abstract
Background: Subacromial pain syndrome (SAPS) is a common complaint in orthopaedics. Subacromial corticosteroid
injections (CSI) can relieve pain in the short term. Anodal transcranial direct current stimulation (a-tDCS) has been used
for symptomatic pain relief in a variety of chronic pain conditions. The aim of this pilot study was to assess whether the
application a-tDCS could enhance the symptomatic relief provided by CSI in patients affected by SAPS.
Methods: Thirty-eight participants (18 to 65-year-old) suffering from SAPS were recruited to have a CSI and randomly
allocated to receive, 1 weeks post CSI, real a-tDCS (r-tDCS), sham tDCS (s-tDCS) or no intervention (Control). Upper limb
function was measured 1 week prior to the CSI, at the 2- and 4-week follow-ups using self-administered questionnaires
and physical measures. Self-reported pain and activity during each day were logged by the participants using visual
analog scales (VAS). Differences between groups were tested using repeated-measures ANOVAs.
Results: Pain VAS and the Single Assessment Numeric Evaluation scale (SANE) showed significant improvement from
baseline 2 weeks and 4 weeks after CSI in all groups (p < 0.05). There were no significant group X time interaction 2
weeks following tDCS treatment in any of the variables.
Conclusion: All groups showed significant improvement in pain VAS and SANE scores following the CSI. One session
of a-tDCS treatment 2 weeks following CSI did not result in any additive or potentializing effects when compared to a
s-tDCS or a control group.
Trial registration: ClinicalTrials.gov, NCT03967574. Registered 30 May 2019 - Retrospectively registered.
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Background
Subacromial pain syndrome (SAPS) is a frequent cause
of shoulder pain and disability in the elective ortho-
paedic surgery practice [1, 2]. This disease, caused by a
spectrum of pathology ranging from subacromial bursitis
to rotator cuff tendinopathy, often leads to shoulder
stiffness and weakness, and subsequent decrease in func-
tion, difficulty performing activities of daily living (ADL),
work disability, and lower overall quality of life [3, 4].
Symptoms usually respond well to conservative interven-
tions such non-steroidal anti-inflammatory medications
(NSAID) and physical therapy (PT) to decrease pain, im-
prove scapular control and maintain shoulder range of
motion [5, 6]. Further pain relief can be obtained with
subacromial corticosteroid injection (CSI) which acts by
reducing the inflammatory response around the tendons.
Multiple meta-analyses have been conducted compar-
ing the effect of CSI to placebo in patients with SAPS.
Mixed results have been reported, but generally a mild
to moderate reduction in pain can be expected in the
short term (less than 6 weeks) [7–10]. When compared
to other interventions, relative efficacy is equivocal. CSI
are superior to NSAID [7], but multiple randomized
controlled trials have shown them inferior to physiother-
apy in the treatment of SAPS patients [11–13]. Newer
types injectable products, such a Platelet-Rich-Plasma
(PRP) and hyaluronic acid, have shown mixed results in
comparison to CSI [14–18]. At this time however, a
positive response to CSI, defined as a reduction in pain
and improvement in function assessed by the patient, is
still considered an important prognostic factor that can
guide the surgeon regarding the suitability of bursect-
omy or acromioplasty, a surgical treatment for persistent
SAPS [19].
Enhancing the effects of CSI with a second non-
invasive intervention could improve its usefulness in the
clinical practice. For example, physiotherapy following a
CSI provides more improvement in SAPS symptoms
than physiotherapy alone [12, 20]. Another intervention,
anodal transcranial direct current stimulation (a-tDCS)
has been gaining attention in the literature and clinical
practice as a mean to reduce pain [21]. Briefly, a-tDCS
involves the continuous application of a weak electric
current over specific areas of scalp for a period of several
minutes using an inexpensive battery-powered device
[22]. When directed over the primary cortical motor
area of the brain (M1), a-tDCS has been shown to in-
crease the excitability of the neurons of this brain region
[23]. a-tDCS is believed to modulate the activity of
cortico-thalamic fibers, inhibiting abnormal thalamic ac-
tivity associated with persistent pain [22]. The wide sur-
face area covered by the tDCS anode might also activate
other neural networks, compounding its effect on pain
[22]. It has been successfully used to improve pain
management in non-specific chronic pain [21], lower
back pain [24], fibromyalgia [25], stroke [26], osteoarth-
ritis [27], and post-op pain [28, 29]. The affordability of
this new technology, coupled with its safe adverse event
profile [21], make it an interesting approach for the
treatment of pain such as is seen in SAPS.
Corticomotor excitability of the rotator cuff M1 repre-
sentation in patients with chronic rotator cuff tendino-
pathy has been shown to be decreased compared to the
contralateral/asymptomatic side [30]. Thus, a-tDCS
could be a valuable add-on intervention to CSI for pa-
tients with subacromial pain syndrome, with each inter-
vention targeting distinct pathophysiological features;
the latter addressing the peripheral/musculoskeletal
component and the former reversing the maladaptive
plasticity of the central nervous system [31]. Somewhat
supporting this view are the results of previous studies
suggesting that tDCS could have a « priming » effect on
other interventions, potentially enhancing their effect by
a synergistic mechanism [24, 32].
Thus, the principal objective of this pilot study was to
explore whether the application of a-tDCS could en-
hance the symptomatic relief provided by CSI in patients
affected by SAPS. The secondary objective was to meas-
ure if this treatment would translate into increased
shoulder use and activity in this sample.
Methods
Study design
Patients (18 to 65-year-old) suffering from SAPS and
scheduled for a CSI were recruited from the orthopedic
service at the Sherbrooke University Hospital Centre
(CIUSS de l’Estrie - CHUS) between January 6th, 2015
and April 30th, 2016 and randomly allocated to receive
at 2 weeks post CSI real a-tDCS (r-tDCS), sham tDCS
(s-tDCS) or no intervention (Control). The protocol
was approved by the local Research Ethics Board
(CIUSSS de l’Estrie – CHUS) and all participants were
required to sign an information and consent form prior
to their inclusion in the study. The protocol followed
CONSORT guidelines and has been retrospectively reg-
istered using original documents initially submitted for
ethics approval (ClinicalTrials.gov Identifier:
NCT03967574). Participants were first seen 1 week
prior to the CSI, at which time they filled in multiple
questionnaires, received a clinical examination, and
were finally given an accelerometer to wear for 5 weeks.
Instruction for home-based exercises, consisting of in-
ternal and external rotation against elastic band resist-
ance (three sets of 10 repetitions per day) were also
given on that initial visit as per the treating orthopedic
surgeon’s usual protocol. They received the CSI 7 days
following the initial assessment. Two-weeks following
the CSI, participants were randomized into one of three
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groups with a ratio of 1:1:1. Block-randomization was
performed by an independent researcher using
computer-generated random numbers and sealed into
sequential envelopes. Physicians and assessors involved
in enrollment, data collection and analysis were kept
blind to group assignment for r-tDCS and s-tDCS until
data collection was completed. Participants of these
groups were also blinded to group assignment, while
participants in the control were aware that they would
not receive any tDCS intervention. Participants were
reassessed 2 weeks (just prior to tDCS treatment) and 4
weeks after the CSI. Outcome variables were patient
self-reported questionnaires, physical examination mea-
sures, and upper extremity use measured by accelero-
metry data. The questionnaires included the Western
Ontario Rotator Cuff index (WORC) as the primary
outcome, the short version of the Disability of the Arm,
Shoulder and Hand questionnaire (QuickDASH), a
daily pain visual analog scale (pain VAS), daily activity
visual analog scale (activity VAS) and the Single Assess-
ment Numeric Evaluation scale (SANE). The physical
examination consisted of shoulder range of motion and
shoulder strength. The time schedule of the study treat-
ments and assessments is summarized into Table 1.
Participants
Patients affected by SAPS on at least one shoulder were
prospectively recruited from the practice of a group of
upper extremity upper orthopaedic surgeons, posters,
and referrals from physiotherapy clinics and family phy-
sicians. Diagnosis of SAPS was made by an orthopaedic
surgeon based on physical examination and clinical
judgment. Inclusion criteria were at least 9 months of
symptoms, presence of a painful arc of movement, and
at least one positive impingement sign (either Neer and/
or Hawkin’s sign). Excluded were any participant pre-
senting clinical or radiographic signs of another shoulder
condition (gleno-humeral or acromio-clavicular osteo-
arthritis, adhesive capsulitis, cervicobrachialgia, rheum-
atic arthritis), clinically determined large rotator cuff
tears, previous shoulder fracture or surgery, and shoul-
der CSI in the last 3 months. Potential participants were
also excluded if they presented any contra-indications to
a-tDCS or transcranial magnetic stimulation (TMS):
presence of an epileptic disorder, metallic implants in
any region of the brain, presence of brain lesion (vascu-
lar, metabolic, traumatic, or neoplastic), consumption of
medication decreasing the convulsion threshold, alcohol-
ism, planned or ongoing pregnancy. Following trial
Table 1 Study participants schedule
Timepoint Treatment/Procedure Outcomes assessed
First assessment Project start
Beginning of home exercises (all patients)
Demographic questionnaire
Baecke physical activity index
WORC (baseline)
QuickDASH (baseline)




Injection visit Subacromial corticosteroid injection (all patients) WORC (pre-injection)
QuickDASH (pre-injection)
Physical examination (pre-injection)
Accelerometer data uploaded into computer




tDCS visit Patients randomized:
- r-tDCS
- s-tDCS




Accelerometer data uploaded into computer







Accelerometer data uploaded into computer
Table 1 shows the distribution of the different assessments and treatment of the study
Abbreviations: tDCS transcranial direct current stimulation, r-tDCS real tDCS, s-tDCS sham tDCS, VAS visual analog scale, SANE single assessment numeric evaluation,
WORC Western Ontario rotator cuff index
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commencement, inclusion criteria were amended to in-
clude participants receiving worker’s compensation in
order to facilitate recruitment efforts. Participants not
eligible or refusing tDCS were also included and allo-
cated to the control group.
Interventions
Corticosteroid injection
The CSI was injected into the subacromial space using
anatomic landmarks on the posterior aspect of the
shoulder by the same fellowship trained shoulder sur-
geon for all participants. It consisted of a mixture of 1
mL of 40 mg methylprednisolone acetate and 4mL of
1% lidocaine and was injected using a 25 bore one-and-
a-half-inch needle.
Anodal transcranial direct current stimulation
The M1 zone for control of the affected rotator cuff ten-
dons was first identified and marked using single pulse
transcranial magnetic stimulation (TMS) and surface
electromyography (EMG) according to the method pre-
viously described by Ngomo et al [30]. Two 5 × 7 cm
tDCS sponge electrodes were soaked in 14 mL of saline
solution to improve conductivity and used as anode and
cathode. The anode was applied on the previously
marked M1 cortical zone for the affected rotator cuff,
while the cathode was applied above the eyebrow
contralateral to the anode position, over the prefrontal
cortex. The assembly was then secured with rubber
bands and adhesive tape (Fig. 1). The study investigator
then left the room while a research technician not in-
volved in the assessment delivered r-tDCS or s-tDCS de-
pending on the participant group assignation using a
battery powered stimulator (Soterix Medical 1 × 1 tDCS
device). The r-tDCS treatment was standardized for all
participants and consisted of a continuous 2 mA stimu-
lation for a duration of 20 min. The s-tDCS participants
only received 30 s of stimulation at 2 mA followed by no
stimulation the rest of the 20 min to mimic the initial
tingling feeling of r-tDCS treatment. This protocol has
been shown to adequately blind the participants in
sham-controlled tDCS studies [33].
Outcome variables
Questionnaires
The WORC and QuickDASH were both completed at
four timepoints: just prior to the CSI injection, 2 weeks
following CSI and prior to a-tDCS treatment, and 4
weeks following CSI. The WORC is a pathology-specific
health-related quality of life questionnaire and has been
well validated for the follow-up of rotator cuff disease
[34]. The final score is reported on a scale from 0 to 100
points, with 100 points representing better function. The
QuickDASH is a more general measure of upper
extremity related quality of life and has been extensively
validated [35–39]. Contrary to the WORC, a score of
100 indicates more severe disability. Daily questionnaires
(pain VAS, activity VAS, and SANE) were also given to
participants and filled for 1 week prior to the injection,
and on the second and fourth week after. Each question-
naire was then averaged over the week measured. Add-
itional baseline characteristics were recorded, such
participant sex, age, dominant upper extremity, affected
shoulder, time since onset of symptoms, Baecke physical
activity index [40], and frequency of repetitive motion
and overhead tasks at work.
Clinical examination
Patient’s shoulder strength and range of motion were
assessed at each follow-up visit. Shoulder range of mo-
tion was measured with an inclinometer in three planes:
abduction, flexion and flexion in the scapular plane
(scaption). Shoulder rotator cuff strength was quantified
with a portable dynamometer with three movements:
Fig. 1 a-tDCS assembly. The anode (a) was applied on the M1
cortical zone for the rotator cuff as identified using TMS. The
cathode (b) was applied over the contralateral eyebrow. The sponge
electrodes where then secured with rubber band and adhesive tape
and soaked in saline
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abduction in scapular plane (Jobe maneuver), internal
rotation with the arm at the side, and external rotation
with the arm at the side.
Upper extremity Accelerometry
A tri-axial accelerometer with a datalogger mounted in a
wearable form factor similar to a wristwatch was used to
quantify upper extremity daily activity (Fig. 2). The plat-
form called WIMU-GPS (Wireless Inertial Measurement
unit with GPS) was developed and assembled at the Re-
search Centre on Aging to allow long term recordings of
motion and location data from inertial sensors and GPS
in a wearable form factor [41, 42]. The triaxial acceler-
ometer (±2/4/8/16 g) was sampled at 50 Hz over the
course of the day and the raw data was stored on a
memory card. The WIMU-GPS was handed to the par-
ticipants at the first evaluation and worn daily for a total
duration of 5 weeks. They were required to wear the de-
vice at all time, except for water-based activity and at
night for recharging. The accelerometer raw data was
downloaded on a computer at each visit and processed
as described in Larrivée, Balg [43]. Following low- and
high-pass filtering (Butterworth, 1 Hz, 2nd Order; then
Butterworth 5 Hz, 2nd Order), a unique acceleration
vector was created using a square root sum calculation.
A 10-s rolling window was then used to detect periods
(or epochs) of activity, defined as epochs containing
more than 50% of data points above a 0.015 g fixed
threshold. The active time (AT) is obtained by summing
the total time of detected activity over the day and divid-
ing this by the total recorded time for that same day.
Each epoch of active time was then integrated and
summed for each day to create an activity count value.
Daily activity count (AC) were defined as the mean ac-
tivity count per minute of active time. Three other vari-
ables were obtained by separating the activity counts in
three categories: low-intensity activities (LIA), moderate-
intensity activities (MIA), and high-intensity activities
(HIA). These were obtained by distributing the activity
counts and defining LIA as activities below the 33rd per-
centile, MIA between the 33rd and 66th percentile, and
HIA above the 66th percentile. These three variables are
reported as a percentage of the total number of activities
detected.
Statistical analyses
Group and time interactions were tested using a
repeated-measures ANOVA with Bonferroni correction
for multiple comparisons. For variables collected over
multiple days (daily activity and pain VAS, SANE, accel-
erometry variables), days were the patients had to
present themselves to clinic removed to reduce observer
effect and avoid collecting activity data on days that are
not usually part of the participant’s routine. All daily
variables were then averaged over 7 days to facilitate
analysis and comparison with the other outcome mea-
sures. The SPSS statistics v22.0 software (IBM, Armonk)
was used for the analysis, and the threshold for signifi-
cance was set at 0.05 for bilateral testing.
As this pilot study was intended to gather data to be
used to assess the feasibility of a larger randomized con-




Thirty-eight participants were recruited in this study: 12
received r-tDCS, 12 s-tDCS and 14 were allocated in the
control group. Two participants refused to undergo
TMS and tDCS and were placed in the control group
(See Fig. 3, CONSORT Flow diagram). Participant’s
characteristics of each group are summarized in Table 1.
There were no significant differences between the three
arms in baseline socio-demographic characteristics,
questionnaire scores, strength, range of motion, or daily
activity (See Tables 2 and 3). All participants were able
to attend the pre-injection, injection, and four-week
visits, but one participant was unavailable for the two-
week assessment. The questionnaires for this patient
were filled in and sent over by mail, but obviously no
clinical examination could be performed at this end-
point. This participant was in the Control group and
thus did not require tDCS treatment. Accelerometer
data collected in the week preceding the injection was
adequate for 24 participants, while they were sufficient
for 22 at the second week following the injection and 19
at the fourth week.
Fig. 2 The WIMU-GPS accelerometer
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Time and group interactions
Table 3 shows mean change in each variable according
to group attribution. (See Table 4) Time X Group inter-
actions were significant for the ratio of MIA (p = 0.005),
ratio of HIA (p = 0.019), and pain VAS (p = 0.047), but
not for any other variables. Pairwise comparisons with
Bonferroni correction did not however yield any signifi-
cant results.
Adverse effects
No major adverse effects were reported by any patient in
any of the study groups. However, some minor effects
were spontaneously reported by participants within their
daily logs. Four participants reported more shoulder pain
following the initial clinical evaluation. Following CSI,
three patients reported an increase in their shoulder
pain, and one reported a headache. One participant from
the s-tDCS group reported headaches after the sham
tDCS intervention. All symptoms resolved within a week
and did not require further medical evaluation.
Discussion
Briefly, despite generally good improvement in all groups
following CSI, no additive or potentializing effect of the
tDCS treatment could be observed in this study, as there
was no significant difference in any variables between
the three groups.
At the end of the study, the sample recruited appeared
to be representative of studied population. Similar to
other studies on the effect of CSI [17, 44, 45], there is an
almost even male to female distribution (52.6%: 47.4%)
and the mean age is within the fourth or fifth decade.
Alvarez, Litchfield [44] and Ekeberg, Bautz-Holter [45]
report the dominant arm to be affected in about two
third of the patients, while it was less so affected in the
present sample (52.6%). Previous studies have shown
that the difference in active time between the dominant
and non-dominant upper extremity was only 30 min per
day [46, 47]. As such, the dominance of the affected limb
might play only a minimal role in the amount of shoul-
der movement detected from the wrist accelerometer
and possibly contributing to daily symptoms. The long
time between the onset of pain to the CSI (average of
71.4 months) might, however, have influenced the re-
sponse to treatment of the injection, as the literature
usually agrees that patients with SAPS respond better to
conservative management when it is started earlier, usu-
ally within 6 months of the onset of symptoms [48–50].
This longer wait time is probably related to local and na-
tional factors secondary to this study being set in a
Fig. 3 CONSORT flow diagram
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publicly funded health-care system. Another Canadian
study on SAPS also had significant wait times (45.6
months) from symptom onset to CSI [44]. Otherwise,
the other participant factors (initial QuickDASH and
WORC scores, BMI, smoking status, comorbidities and
depression) were similar to previously published studies
on SAPS. While not reaching statistical significance, dis-
tribution of baseline scores between groups shows trends
toward important differences that might have affected
final outcomes. Notably, and despite a thorough
randomization process, baseline WORC and SANE
scores were lower in the Control group than both r-
tDCS and s-tDCS groups, while the inverse was true for
QuickDASH and pain VAS (representing worse function
or pain).
The only questionnaire showing a group and time
interaction was the pain VAS. Despite not showing any
significance after pairwise comparison and Bonferroni
correction, there is a clear trend for the Control group
showing larger decrease in pain than both tDCS groups.
This is likely related to the higher pain scores seen at
baseline for these participants, giving them a better po-
tential for improvement. Randomization of the
participants according to their baseline scores has been
proposed to minimize this potential bias [51].
MIA and HIA showed significant group and time
interaction but not significant after post-hoc Bonferroni
tests. Trends show the MIA to increase and HIA to de-
crease in the r-tDCS group compared both s-tDCS and
Control groups. Lack of significant improvement could
be related to low sample size. Using sensitivity to change
information from a previous publication of the present
authors [43], a sample size between 22 and 70 patients
would be necessary to be powered at 80% at 4 weeks, de-
pending on the variable chosen. With only 19 acceler-
ometers having valid data at baseline and 4 weeks, this
threshold was not met. It is also conceivable that the
subjective improvement in pain and function felt by the
participants did not translate in a sizeable increase in
their upper extremity activity. This hypothesis is sup-
ported by the fact that no statistically significant change
in activity VAS was noted. This, however, contrasts
some studies showing a significant change in kinematic
scores after surgical repair of the rotator cuff [52–55].
Nevertheless, these studies differ significantly from the
present study in terms of pathology, treatment and
Table 2 Baseline participants characteristics
Variable r-tDCS group s-tDCS group Control All groups
Number of participants 12 12 14 38
Sex Male: 6 (50%) Male: 7 (58.3%) Male: 7 (50%) Male: 20 (52.6%)
Female: 6 (50%) Female: 5 (41.7%) Female: 7 (50%) Female: 18 (47.4%)
Age (years ± SD) 52.0 ± 10.3 years 44.1 ± 6.9 years 50.2 ± 12.1 years 48.8 ± 10.4 years
Body mass index (BMI ± SD) 27.21 ± 5.0 28.7 ± 5.9 27.7 ± 4.36 27.9 ± 5.0
Dominant upper extremity Right: 11 (91.7%) Right: 10 (82.3%) Right: 11 (78.6%) Right: 32 (84.3%)
Left: 1 (8.3%) Left: 2 (16.7%) Left: 3 (21.4%) Left: 6 (15.7%)









Time since onset of symptoms (months ±
SD)
82.3 ± 75.3 months 88.6 ± 106.2 months 48.1 ± 50.3 months 71.4 ± 79.3 months
Baecke physical activity index (score ± SD) 8.7 ± 1.4 8.6 ± 1.9 9.1 ± 1.4 8.8 ± 1.5
Frequency of repetitive motions at work Never: 1 (8.3%) Never: 0 (0%) Never: 0 (0%) Never: 1 (2.6%)
Rarely: 1 (8.3%) Rarely: 1 (8.3%) Rarely: 2 (14.3%) Rarely: 4 (10.6%)
Sometimes: 3 (25%) Sometimes: 3 (25%) Sometimes: 2 (14.3%) Sometimes: 8 (21.1%)
Often: 3 (25%) Often: 4 (33.3%) Often: 3 (21.4%) Often: 10 (26.3%)
Very often: 4 (33.3%) Very often: 4 (33.3%) Very often: 7 (50%) Very often: 15 (39.5%)
Frequency of overhead tasks at work Never: 2 (16.7%) Never: 0 (0%) Never: 0 (0%) Never: 3 (5.3%)
Rarely: 4 (33.3%) Rarely: 4 (33.3%) Rarely: 3 (21.4%) Rarely: 11 (28.9%)
Sometimes: 3 (25%) Sometimes: 6 (50%) Sometimes: 3 (21.4%) Sometimes: 12 (31.6%)
Often: 1 (8.3%) Often: 1 (8.3%) Often: 6 (42.9%) Often: 8 (21.1%)
Very often: 2 (16.7%) Very often: 1 (8.3%) Very often: 2 (14.3%) Very often: 5 (13.2%)
Results shown as: total number (frequency %) unless otherwise noted
Abbreviations: tDCS transcranial direct current stimulation, r-tDCS real tDCS, s-tDCS sham tDCS, SD standard deviation
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outcome variables, more than likely explaining the
difference.
Additional explanations can be offered for the lack of
effect of tDCS on pain. Firstly, the effects of tDCS on
musculoskeletal pain are not well understood. While
some studies with small number of participants have
shown improvement in patients with non-specific
chronic pain, lower back pain, and fibromyalgia [21, 24,
25], the well constructed trial by Luedtke, Rushton [56]
was unable to show any additional effect of tDCS when
done in conjunction with cognitive behavioral therapy
for patients with low back pain. This study was a ran-
domized double-blinded trial with a total of 135 partici-
pants (67 per group). Furthermore, the study by Belley,
Mercier [57] explored the additive effects of tDCS and
rehabilitation with sensorimotor training on patients
with SAPS. Their trial was similar to the present trial in
population studied and outcomes, and they were unable
to detect any potentializing effect of the tDCS treatment
either. It is also possible that the improvement shown
with CSI may reach a ceiling effect. In contrast to earlier
studies [12, 20], a 2016 randomized controlled trial did
not show any additional affect of exercise therapy after a
CSI [58].
The timing and dose of tDCS might also have played a
role in the lack of tDCS effects. While this protocol only
included 120 min treatment, recommended tDCS regi-
mens usually consists of five daily treatments of 20–30
min each [59]. This regimen was chosen to reduce the
number of participant visits, facilitate compliance to
protocol, and document the effect of a single dose of
tDCS as add-on to CSI. Fregni, Boggio [60] showed an
additive effect of multiple sessions, with a clinically sig-
nificant improvement compared to placebo only appre-
ciable after three treatments. In a preliminary study on
patients with lower back pain, significant improvements
after a single session were only observed on experimen-
tal thermal pain thresholds but not on other aspects of
pain [61]. Furthermore, tDCS might have had more ef-
fect on shoulder symptoms if it was provided before the
CSI, as some studies have shown enhanced effects of
subsequent treatment when tDCS is applied before, in
contrast to after, the second intervention [32, 62]. It is
also possible that a ceiling effect might have been
reached after the CSI for most outcome measures, mak-
ing it more difficult to detect additional improvements
provided by the tDCS treatment. Finally, as most partici-
pants still had good relief at 4 weeks following the CSI, a
longer follow-up period might have uncovered a
prolonging effect of the tDCS treatment after 4 weeks.
Strengths of the study included strict inclusion criteria
which ensured that only one pathology was followed and
Table 3 Baseline participant scores
Outcome measure r-tDCS group s-tDCS group Control All groups
WORC 56.70 (17.69) 43.66 (22.20) 40.66 (15.96) 46.88 (18.86)
QuickDASH 27.58 (13.46) 44.43 (20.75) 42.41 (21.85) 42.85 (18.07)
Pain VASa 48.26 (20.65) 53.58 (19.11) 61.84 (15.41) 54.94 (18.76)
Activity VASa 59.02 (22.01) 55.78 (22.35) 59.69 (19.80) 58.24 (20.82)
SANEa 56.67 (17.68) 57.00 (16.40) 47.56 (19.05) 53.42 (17.92)
Strength (kg)
- Jobe 7.82 (3.90) 8.09 (2.44) 7.92 (3.95) 8.11 (3.45)
- External rotation 8.56 (3.95) 9.57 (2.97) 9.23 (4.32) 9.27 (3.69)
- Internal rotation 13.27 (5.55) 13.29 (4.55) 13.60 (6.30) 13.60 (5.34)
Range of motion (°)
- Abduction 160.83 (22.85) 164.33 (17.23) 160.14 (26.03) 161.86 (22.30)
- Flexion 157.92 (13.67) 163.50 (15.50) 155.64 (25.07) 159.49 (18.78)
- Scaption 159.75 (17.39) 170.18 (13.55) 159.14 (21.39) 163.75 (17.17)
Accelerometer
- AT 0.5320 (0.1306) 0.5346 (0.0490) 0.4554 (0.1469) 0.50 (0.12)
- AC 317.19 (50.21) 329.61 (72.85) 293.06 (44.94) 309.75 (55.48)
- LIA 0.0567 (0.0260) 0.0490 (0.0140) 0.0646 (0.0217) 0.058 (0.021)
- MIA 0.2054 (0.0821) 0.2185 (0.1032) 0.2214 (0.0593) 0.217 (0.076)
- HIA 0.7609 (0.0973) 0.7531 (0.1122) 0.7367 (0.0714) 0.748 (0.088)
Results shown as Mean (SD)
Abbreviations: SD Standard Deviation, AT active time, AC activity count, LIA low intensity activity, MIA medium intensity activity, HIA high intensity activity, VAS
visual analog scale
aArithmetic mean for the first week
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improving internal validity of the study. The follow-up
rate was excellent, with no participant lost to follow-up.
Utilisation of well validated questionnaires as well as
more objective outcome measures such as accelerometry
were also strengths of this protocol. The M1 area for the
rotator cuff was localized using TMS in every partici-
pant, ensuring the tDCS treatment was delivered accur-
ately at the intended target. The use of a randomized
double-blind design also allows for increase internal
validity.
However, some limitations must also be brought for-
ward. Being a pilot study, the resulting of low number of
participants may have explained the lack of power to de-
tect a significant change between the groups. Using
means and variance of the WORC score, this study
achieved a power of 65.8%. The data from this pilot
study can be used to determine that a minimum of 51
participants would be required to attain a power of 80%
with an alpha set at 0.05. Despite strict inclusion criteria,
no MRIs were performed to completely exclude other
confounding pathologies. These strict inclusion criteria
also reduce the external validity of the results. One of
these criteria, the requirement of 9 months of symptoms
prior to inclusion, also probably explains the large pro-
portion of chronic SAPS in the sample. This choice was
made to ensure that the SAPS would not self-resolve, as
they can usually do within the first few months, and to
align with referral criteria in place in the centre were
this study was conducted. It is also worth noting that
there are no gold standard clinical test to diagnose SAPS
[63]. Randomization might have also been less successful
than anticipated as the control group showed trends to
worse baseline scores than the two other groups. The
data was analysed on a “as treated” basis, in contrast to
the “intention to treat” analysis that is recommend in
randomized controlled trials. While no participants
switched groups or assignation during the study, two pa-
tients who agreed to participate in the study declined to
receive tDCS treatment. These patients were still in-
cluded to increase the power of the study but may have
biased the randomization process and the estimate of
the efficacy of the intervention. Furthermore, the pa-
tients were only followed for 4 weeks after the CSI, and it
is possible that a delayed effect might have been missed.
However, a longer follow-up could have resulted in diffi-
culty reaching target sample size and ensuring compliance
Table 4 Effect of the injection at two and four weeks




r-tDCS s-tDCS Control r-tDCS s-tDCS Control
WORC 8.96 (17.61) 15.66 (17.41) 28.89 (23.37) 10.67 (17.51) 12.81 (16.88) 26.04 (27.41) 0.072
QuickDASH −10.13 (22.56) − 8.28 (12.88) − 18.05 (16.24) −8.64 (16.11) − 7.61 (10.61) − 14.68 (20.14) 0.366
Pain VASa −15.23 (12.40) − 15.33 (20.06) −28.82 (20.82) −18.36 (20.13) − 16.49 (14.83) −35.81 (21.33) 0.047
Activity VASa 6.20 (13.91) 0.87 (18.41) 13.57 (22.96) 4.57 (12.53) 4.67 (22.23) 11.02 (29.08) 0.430
SANEa 18.17 (18.21) 10.79 (15.10) 25.89 (18.82) 20.50 (20.20) 11.53 (12.62) 29.53 (18.98) 0.058
Strength (kg)
- Jobe −0.47 (3.52) −1.42 (3.31) −0.92 (2.44) − 0.11 (3.45) − 1.17 (2.96) − 0.60 (2.66) 0.694
- Ext rotation 0.64 (2.10) 0.83 (1.45) 0.49 (1.58) 1.44 (2.57) 1.64 (1.16) 1.24 (2.42) 0.803
- Int rotation 0.69 (2.03) 0.76 (2.01) 0.44 (2.59) 1.68 (2.24) 1.89 (2.05) 0.64 (3.45) 0.178
ROM (°)
- Abduction −2.75 (14.55) 3.00 (16.03) 6.62 (17.25) 1.50 (18.94) 3.67 (13.49) 7.64 (15.64) 0.644
- Flexion 3.83 (18.85) −0.33 (14.69) 3.31 (9.47) 0.75 (8.83) 0.17 (13.37) 8.14 (13.25) 0.626
- Scaption −2.92 (15.61) −1.36 (7.23) 3.31 (9.75) 2.58 (11.63) −1.27 (7.27) 5.36 (13.04) 0.528
Accelerometera
- AT −0.0653 (0.0382) − 0.0235 (0.0517) 0.5339 (0.13) −0.585 (0.0524) 0.0063 (0.0362) 0.0176 (0.1523) 0.159
- AC −8.51 (14.81) −23.81 (36.65) −3.44 (40.60) − 8.35 (63.45) −31.02 (14.37) −7.65 (25.18) 0.684
- LIA 0.0182 (0.0153) 0.0061 (0.0097) −0.0149 (0.0289) 0.0255 (0.0302) 0.0142 (0.0053) −0.0024 (0.0193) 0.338
- MIA 0.0363 (0.0141) −0.0128 (0.0322) 0.0141 (0.1085) 0.0018 (0.0243) 0.0423 (0.0605) 0.0137 (0.0301) 0.005
- HIA −0.0488 (0.0188) 0.0084 (0.0314) −0.0007 (0.1240) −0.0245 (0.0474) − 0.0534 (0.0639) −0.0100 (0.0387) 0.019
Results shown as Mean (SD)
Abbreviations: SD Standard Deviation, Gr Group, Wk week, AT active time, AC activity count, LIA low intensity activity, MIA medium intensity activity, HIA high
intensity activity, VAS visual analog scale, Ext external, Int internal
aChange calculated from the average of the pre-injection week. and second and fourth week after the injection
Larrivée et al. BMC Musculoskeletal Disorders          (2021) 22:265 Page 9 of 12
with accelerometer wear. Some studies have also brought
into question the adequateness of blinding sham tDCS in
amplitudes of 2mA [64]. Using only one tDCS session,
provided after the intervention it is supposed to
potentialize, might also explain the lack of effect, as ex-
plained previously. Finally, data loss from the accelerom-
eter is a significant limitation of the study, decreasing the
usability of this outcome measure in this study.
Conclusions
One session of anodal tDCS treatment 2 weeks following
CSI did not result in any additive or potentializing ef-
fects when compared to a sham tDCS or a Control
group. Further studies should explore effects repeated
tDCS sessions prior to the injection to improve the
potentialization effect as well as interaction with other
treatments such as physiotherapy.
Abbreviations
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